Investment Analysts’ Weekly Ratings Updates for Alvotech (ALVO)

A number of firms have modified their ratings and price targets on shares of Alvotech (NASDAQ: ALVO) recently:

• 4/5/2026 – Alvotech was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/28/2026 – Alvotech was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/24/2026 – Alvotech had its price target lowered by UBS Group AG from $10.00 to $6.00. They now have a “buy” rating on the stock.
• 3/24/2026 – Alvotech had its price target lowered by Barclays PLC from $5.00 to $4.00. They now have an “underweight” rating on the stock.
• 3/19/2026 – Alvotech was upgraded by Zacks Research from “strong sell” to “hold”.
• 2/18/2026 – Alvotech was downgraded by Zacks Research from “hold” to “strong sell”.

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).